[Long-term treatment of schizophrenic patients with leponex (clozapine)].
The authors studied a prolonged (3--5 years) use of leponex in 23 patients with the most progressive forms of schizophrenia (hebephrenic, paranoid and close to them attack-like). The study included the influence on the frequency and duration of relapses, on the dynamics of the so-called productive and negative disorders and social adaptation. The achieved data indicate that leponex possesses certain advantages compared to other neuroleptical drugs in prolonged maintenance therapy. Leponex has a rather "universal" psychopharmacological effect which includes a capability of arresting acute psychoses, exerts a psychoregulating influence on the general behaviour, contacts and socio-working adaptation, distinctly alleviates the clinical signs and frequency of relapses. Due to the absence of motor disturbances and minimum of other side-effects leponex is quite convenient for prolonged use and promotes a higher quality of remissions.
D000328:Adult; D002908:Chronic Disease; D003024:Clozapine / Q000008:administration & dosage*; D003984:Dibenzazepines / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012559:Schizophrenia / Q000188:drug therapy*; D012562:Schizophrenia, Disorganized / Q000188:drug therapy; D012563:Schizophrenia, Paranoid / Q000188:drug therapy; D012917:Social Adjustment; D013577:Syndrome; D013997:Time Factors
D003984:Dibenzazepines; D003024:Clozapine
Dlitel'noe lechenie leponeksom (klozapinom) bol'nykh schizofrenieĭ.